CXCL16 can target MG and induce upregulation of the p65 subunit of NF-κB and phospho-ERK1/2 and synthesis and secretion of VEGF (Abu El-Asrar et al., 2020). This evidence concerns the gene MAPK3 and myasthenia gravis.